Speak With A Cord Blood Expert To Learn More
Call Toll-Free 1-877-543-3226
LIFEBANKUSA
LifebankUSA®’s long and successful history of providing stem cells for potentially debilitating and life-threatening diseases is the ultimate validation of its processing and storage methods. LifebankUSA is also the only cord blood bank in the US that has released combined placenta-derived and cord blood stem cells for treatment.
LifebankUSA® Cord Blood Units Released for Transplant
Standard Therapies
| # | Date of Transplant | Age of patient | Disease | Time Unit Stored |
|---|---|---|---|---|
| 1 | 8/27/2003 | 6 months | Acute Myelogenous Leukemia (AML) | 2 years, 5 months |
| 2 | 11/19/2004 | 4 years | Acute Myeloblastic Leukemia | 1 year, 1 month |
| 3 | 2/23/2005 | 10 years | Myelodysplastic Syndrome (MDS), Wilm's Tumor | 2 years |
| 4 | 5/26/2005 | 34 years | Non-Hodgkin's Lymphoma(NHL) | 10 months |
| 5 | 7/12/2005 | 9 years | Acute Myelogenous Leukemia (AML)- 2nd Remission | 1 year, 8 months |
| 6 | 7/25/2005 | 3 years | Chediak-Higashi Syndrome | 2 years, 3 months |
| 7 | 8/20/2005 | 35 years | Acute Myelogenous Leukemia (AML)- 2nd Remission | 2 years, 1 month |
| 8 | 4/13/2006 | 7 months | Myelodisplasia (MDS) | 2 years, 7 months |
| 9 | 5/26/2006 | 20 months | Acute Myelogenous Leukemia (AML) | 2 years, 7 months |
| 10 | 6/14/2006 | 8 years | Acute Myelogenous Leukemia (AML) | 2 years, 10 months |
| 11 | 7/12/2006 | 5 years | Acute Myelogenous Leukemia (AML) | 3 years |
| 12 | 8/29/2006 | 35 years | Acute Myelogenous Leukemia (AML) | 3 years, 2 months |
| 13 | 1/30/2007 | 3 years | Acute Myelogenous Leukemia (AML) | 3 years, 7 months |
| 14 | 8/16/2007 | 2 years | Chediak-Higashi Syndrome | 3 years, 11 months |
| 15 | 7/27/2007 | 1 year | Severe Combined Immunodeficiency | 3 years, 5 months |
| 16 | 2/19/2008 | 50 years | Non-Hodgkin’s Lymphoma(NHL) - relapse | 2 years, 2 months |
| 17 | 3/28/2008 | 5 years | Acute Lymphoblastic Leukemia (ALL) | 3 months |
| 18 | 4/25/2008 | 11 years | Acute Lymphoblastic Leukemia (ALL) | 4 years, 9 months |
| 19 | 7/3/2008 | 50 years | Chronic Lymphocytic Leukemia (CLL) | 5 years, 8 months |
| 20 | 7/24/2008 | 3 years | Sickle Cell Anemia | 4 years, 3 months |
| 21 | 6/23/2008 | 2 years | Acute Myelogenous Leukemia (AML) | 4 years, 1 month |
| 22 | 12/30/2008 | 47 years | Myeloproliferative Disease/Acute Myelogenous Leukemia (AML) | 5 years, 7 months |
| 23 | 1/21/2009 | 17 months | Sickle Cell Anemia | 4 years, 7 months |
| 24 | 1/16/2009 | 24 years | Inherited Bone Marrow Failure Syndrome | 4 years, 9 months |
| 25 | 5/19/2009 | 23 months | In utero Stroke | 1 year, 11 months |
LifebankUSA® Cord Blood Units Released for Transplant
Investigational Therapies
| # | Date of Transplant | Age of patient | Disease | Time Unit Stored |
|---|---|---|---|---|
| 1 | 7/6/2005 | 1 year | Hurler's Syndrome * | 1 year, 8 months |
| 2 | 8/1/2007 | 1.5 years | Langerhans Histiocytosis * | 3 years, 3 months |
| 3 | 3/18/2008 | 2 years | Cerebral Palsy * | 2 years, 2 months |
*These are diseases for which stem cell treatments have been shown to be potentially beneficial, but additional studies are required before they can be used as standard therapy.These investigational uses are not consistent with current labeling. Stem cells from the placenta and cord blood are indicated to rebuild blood.
Banking placenta stem cells can substantially increase the number of stem cells available for treatment, compared to cord blood alone. LifebankUSA, through its Placenta-Cord banking service, released stem cells from both the placenta and the cord blood for groundbreaking treatment (3/28/08 transplant above) that enabled the patient to be treated with more than double the number of CD34+ stem cells, the stem cells that matter for treatment success and patient survival, than had only the cord blood been available. Clinical studies have shown that transplanting more CD34+ stem cells can lead to improved treatment success and patient survival.1-5
Placenta-Cord Transplant Details:
- The ongoing clinical study: The March 28, 2008 transplant is part of a multicenter clinical trial to evaluate the safety and efficacy of transplanting umbilical cord blood together with human placenta-derived stem cells in children with a range of malignant hematologic (blood-forming) diseases and non-malignant disorders.6 Early data suggest safety and potential benefits.
- The transplant success story: In 2007, a family banked its baby's placenta-derived stem cells and cord blood stem cells with LifebankUSA. On March 28, 2008, the baby's older brother underwent a transplant using both placenta-derived and cord blood units to treat acute lymphoblastic leukemia (ALL).
- The Placenta-Cord Advantage: “Engraftment occurred earlier than anticipated. The patient is doing extremely well and was discharged from the hospital 1 to 2 weeks earlier, compared to traditional cord blood transplants.” – Lolie C. Yu, MD - Transplanting Physician. Professor of Pediatrics; Division Chief, Pediatric Heme-Onc Program; and Director, BMT Program, Children's Hospital, New Orleans.
“I recommend banking placenta-derived stem cells and cord blood because it gives you the most cells possible—including more of the stem cells that matter most for a potentially lifesaving transplant. LifebankUSA is the only cord blood banking company that provides placenta-derived stem cells and cord blood stem cell banking to families.”
—Mitchell S. Cairo, MD | Chief of the Pediatric Blood and Marrow Transplantation Division at the Morgan Stanley Children’s Hospital of New York-Presbyterian and Professor of Pediatrics, Medicine and Pathology at Columbia University and a pioneer in the use of cord blood stem cells for transplant.
"I am a repeat LifebankUSA customer. This time around, we had the chance to bank both placenta-derived stem cells and cord blood. Only LifebankUSA offered this option. My wife and I wanted the best protection for our family, so we banked both. We have greater peace of mind knowing we collected the most cells possible. Thank you LifebankUSA."
-Dave S., New Jersey
LifebankUSA can provide substantially more potentially lifesaving cells for treatment - clinical studies have shown that using more cells greatly increased the chances of treatment success and patient survival. And, LifebankUSA cord blood units are on average 99% pure.
Click here for a free information kit and call our cord blood experts toll-free 1-877-543-3226 for more information on:
- How stem cells from cord blood have saved thousands of lives.
- How only LifebankUSA can provide you with the most stem cells possible, which can improve treatment success and patient survival.
- What you need to know about cord blood purity.
